MedTrace Logo

A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer

NCT02747342 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2020-07-21

No results posted yet for this study

Summary

This is a multicenter, dose-escalation/expansion phase 1 trial to evaluate the safety, tolerability and efficacy of SHR3680 with or without SHR3162 given orally to subjects with metastatic castration-resistant prostate cancer (mCRPC).

Conditions

Interventions

DRUG

SHR3680; SHR3162

SHR3680 will be administered orally in dose escalation/expansion phase, SHR3680 will be administered orally at a fixed dose together with SHR3162 in combination phase.

Sponsors & Collaborators

  • Atridia Pty Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2019-06-28
Completion
2020-06-28

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02747342 on ClinicalTrials.gov